Journal article
Causes of Death in Low Grade B-Cell Lymphomas in the Rituximab Era: A Prospective Cohort Study
Blood advances, Vol.6(17), pp.5210-5221
07/18/2022
DOI: 10.1182/bloodadvances.2022007990
PMCID: PMC9631639
PMID: 35849723
Abstract
Low-grade B-cell lymphomas other than follicular and small lymphocytic lymphoma (LGBCL) account for 10% of all B-cell non-Hodgkin lymphomas. Despite improvements in survival outcomes for these patients, little is known about cause of death (COD) in the rituximab era. For a better understanding, we studied 822 newly diagnosed patients with marginal zone, lymphoplasmacytic, and unclassifiable low-grade B-cell lymphoma prospectively enrolled in the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource from 2002 to 2015. COD was assigned based on medical record review using a standard protocol. At a median follow-up of 107 months, 219 (27%) patients had died. The incidence of lymphoma-related deaths when pooling across subtypes was lower than non–lymphoma-related deaths (10-year incidence, 8.0%; 95% confidence interval [CI]: 6.2-10.4 vs 13.6%; 95% CI: 11.2-16.6). The incidence of lymphoma-related deaths varied by subtype, ranging from 3.7% at 10 years in extranodal marginal zone lymphoma to 19.3% in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Patients with early progression or retreatment events, defined using event-free survival at 24 months from diagnosis, had significantly higher likelihood of lymphoma-related death compared with patients without early events (10-year estimate: 19.1% vs 5.1%, respectively; P, .001), whereas the rates for non–lymphoma-related death were comparable in patients with or without early events (10-year estimates: 11.0% vs 15.3%, respectively). In conclusion, the most common COD in LGBCLs in the first decade after diagnosis was for causes other than lymphoma. Progression or retreatment within the first 2 years of diagnosis was a strong predictor for risk of lymphoma-related death.
Details
- Title: Subtitle
- Causes of Death in Low Grade B-Cell Lymphomas in the Rituximab Era: A Prospective Cohort Study
- Creators
- Aung Tun - University of Kansas Medical CenterArushi Khurana - Mayo Clinic, Rochester, Minnesota, United States.Raphael Mwangi - Mayo Clinic, Rochester, Minnesota, United States.Brian K Link - University of IowaYucai Wang - Mayo Clinic, Rochester, Minnesota, United States.Andrew Feldman - Mayo Clinic, Rochester, Minnesota, United States.Carrie A Thompson - Mayo ClinicAnne J Novak - Mayo Clinic, Rochester, Minnesota, United States.Jose Caetano Villasboas - Mayo Clinic, Rochester, Minnesota, United States.Gita Thanarajasingam - Mayo Clinic, Rochester, Minnesota, United States.Umar Farooq - University of IowaSergei I Syrbu - University of IowaGrzegorz S Nowakowski - Mayo Clinic, Rochester, Minnesota, United States.Thomas E Witzig - Mayo ClinicStephen M Ansell - Mayo Clinic, Rochester, Minnesota, United States.Lisa M Rimsza - Mayo Clinic, Scottsdale, Arizona, United States.James R Cerhan - Mayo ClinicThomas M Habermann - Mayo ClinicMatthew J Maurer
- Resource Type
- Journal article
- Publication Details
- Blood advances, Vol.6(17), pp.5210-5221
- DOI
- 10.1182/bloodadvances.2022007990
- PMID
- 35849723
- PMCID
- PMC9631639
- NLM abbreviation
- Blood Adv
- ISSN
- 2473-9529
- eISSN
- 2473-9537
- Language
- English
- Date published
- 07/18/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Pathology; Internal Medicine
- Record Identifier
- 9984296302802771
Metrics
41 Record Views